危重症患者接受药物血栓预防时VTE风险评估模型的效能:PREVENT试验事后分析
该研究为PREVENT试验事后分析,纳入2003例接受药物血栓预防的危重症患者,评估6种VTE风险评估模型的预测效能。198例(9.9%)发生VTE,除Caprini模型AUC为0.64(95%CI 0.60-0.68)外,其余模型AUC均<0.60。各模型阳性预测值均<20%,阴性预测值多>90%,且未能识别可从联合气压压缩治疗获益的亚组。
要点
- 危重症药物血栓预防患者中VTE发生率9.9%,现有风险评估模型区分度普遍较差。
- Caprini模型AUC仅0.64,其余模型AUC均<0.60,预测效能有限。
- 各模型阳性预测值均<20%,不能可靠识别高危患者,但阴性预测值多>90%。
核心结论
- 在接受药物血栓预防的危重症患者中,现有VTE风险评估模型预测效能差。
- 无模型能识别可能从联合气压压缩治疗中获益的亚组。
研究设计与样本
- PREVENT试验(气压压缩预防VTE)的事后分析。
- 纳入2003例接受药物血栓预防的危重症患者,评估ICU-VTE、Kucher、Intermountain、Caprini、Padua和IMPROVE共6种VTE风险评估模型。
- 构建受试者工作特征曲线,计算灵敏度、特异度、阳性与阴性预测值及阳性与阴性似然比,并按模型风险分层进行亚组分析比较联合气压压缩与单纯药物预防的效应。
主要发现
- 2003例中198例(9.9%)发生VTE。
- 多因素logistic回归显示VTE独立预测因素为APACHE II评分、既往制动、股静脉中心静脉导管和侵入性机械通气。
- 除Caprini模型AUC为0.64(95%CI 0.60-0.68)外,所有模型AUC均<0.60。
- Caprini、Padua和Intermountain模型预测VTE灵敏度>85%但特异度<20%;ICU-VTE、Kucher和IMPROVE模型灵敏度<15%但特异度>85%。
- 所有研究截断值的阳性预测值均<20%,阴性预测值多>90%。
关键数值与推荐
- VTE发生率:198/2003(9.9%)。
- Caprini模型AUC 0.64(95%CI 0.60-0.68),其余模型AUC<0.60。
- 高灵敏度低特异度模型:Caprini、Padua、Intermountain(灵敏度>85%,特异度<20%)。
- 低灵敏度高特异度模型:ICU-VTE、Kucher、IMPROVE(灵敏度<15%,特异度>85%)。
- 所有截断值阳性预测值<20%,阴性预测值多>90%;亚组交互作用Pinteraction > .05。
临床怎么用
- 不应单独依赖现有VTE风险评估模型决定危重症药物血栓预防患者的联合气压压缩治疗。
- 模型阴性预测值较高,或有助于排除VTE低风险患者,但阳性预测值低,不能可靠识别高危患者。
- 临床决策应结合APACHE II评分、制动、股静脉导管和机械通气等独立预测因素综合评估。
局限性
- 为PREVENT试验的事后分析,结果属探索性。
- 仅纳入接受药物血栓预防的危重症患者,结论外推受限。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnostic performance of the available risk assessment models for VTE in patients who are critically ill receiving pharmacologic thromboprophylaxis is unclear. RESEARCH QUESTION: For patients who are critically ill receiving pharmacologic thromboprophylaxis, do risk assessment models predict who would develop VTE or who could benefit from adjunctive pneumatic compression for thromboprophylaxis? STUDY DESIGN AND METHODS: In this post hoc analysis of the Pneumatic Compression for Preventing VTE (PREVENT) trial, different risk assessment models for VTE (ICU-VTE, Kucher, Intermountain, Caprini, Padua, and International Medical Prevention Registry on VTE [IMPROVE] models) were evaluated. Receiver-operating characteristic curves were constructed, and the sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were calculated. In addition, subgroup analyses were performed evaluating the effect of adjunctive pneumatic compression vs none on the study primary outcome. RESULTS: Among 2,003 patients receiving pharmacologic thromboprophylaxis, 198 (9.9%) developed VTE. With multivariable logistic regression analysis, the independent predictors of VTE were Acute Physiology and Chronic Health Evaluation II score, prior immobilization, femoral central venous catheter, and invasive mechanical ventilation. All risk assessment models had areas under the curve < 0.60 except for the Caprini model (0.64; 95% CI, 0.60-0.68). The Caprini, Padua, and Intermountain models had high sensitivities (> 85%) but low specificities (< 20%) for predicting VTE, whereas the ICU-VTE, Kucher, and IMPROVE models had low sensitivities (< 15%) but high specificities (> 85%). The positive predictive values were low (< 20%) for all studied cutoff scores, whereas the negative predictive values were mostly > 90%. Using the risk assessment models to stratify patients into high- vs low-risk subgroups, the effect of adjunctive pneumatic compression vs pharmacologic prophylaxis alone did not differ across the subgroups (Pinteraction > .05). INTERPRETATION: The risk assessment models for VTE performed poorly in patients who are critically ill receiving pharmacologic thromboprophylaxis. None of the models identified a subgroup of patients who might benefit from adjunctive pneumatic compression. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, No.: NCT02040103, URL: www. CLINICALTRIALS: gov. ISRCTN44653506; International Standard Randomised Controlled Trial No.: ISRCTN44653506, URL: https://www.isrctn.com.
引用
- Al-Dorzi HM, Arishi H, Al-Hameed FM, et al. Performance of Risk Assessment Models for VTE in Patients Who Are Critically Ill Receiving Pharmacologic Thromboprophylaxis: A Post Hoc Analysis of the Pneumatic Compression for Preventing VTE Trial. Chest. 2024. PMID: 39232999. doi:10.1016/j.chest.2024.07.182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。